6533b828fe1ef96bd1287921
RESEARCH PRODUCT
The evolutionary scenario of hepatocellular carcinoma in Italy: an update
Laura BucciFrancesca GarutiBarbara LenziAnna PecorelliFabio FarinatiEdoardo GianniniAlessandro GranitoFrancesca CiccareseGian Lodovico RapacciniMaria Di MarcoEugenio CaturelliMarco ZoliFranco BorzioRodolfo SaccoCalogero CammàRoberto VirdoneFabio MarraMartina FelderFilomena MoriscoLuisa BenvegnùAntonio GasbarriniGianluca Svegliati BaroniFrancesco Giuseppe FoschiGabriele MissaleAlberto MasottoGerardo NardoneAntonio ColecchiaMauro BernardiFranco TrevisaniMaurizio BiselliPaolo CaraceniAlessandro CucchettiMarco DomenicaliAnnagiulia GramenziDonatella MagalottiLucia NapoliGiulia NegriniFabio PiscagliaCarla SerraFrancesco TovoliFilippo MarafattoFrancesca MurerGiulia PesericoCaterina PozzanVeronica VaninAlessandro MoscatelliGaia PellegattaAntonino PicciottoVincenzo SavarinoPaolo Del PoggioStefano OlmiNicoletta De MatthaeisClaudia BalsamoElena VavassoriPaola RoselliSerena Dell’isolaAnna Maria IalungoElena RastrelliMaria Rosa BarcellonaGiuseppe CabibboAndrea CostantinoMarcello MaidaAndrea AffrontiAndrea MegaEmanuele RinninellaValeria MismasAnna Chiara Dall’aglioValentina FelettiArianna LanziFederica Mirici CappaElga NeriGiuseppe Francesco StefaniniStefano TamberiElisabetta BiasiniEmanuela PorroMaria GuarinoStefano GeminiLaura SchiadàMaria ChiaramonteFabiana MarchettiMatteo ValerioAlberta CappelliRita GolfieriCristina MosconiMatteo RenzulliPiero CoccoliMarco Sanduzzi ZamparelliSami AburasAndrea Lorenzo Inghilesisubject
OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusinessdescription
Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinomas; 3) increasing proportion of hepatocellular carcinoma diagnosed during a correct (semiannual) surveillance program; 4) favourable cancer stage migration; 4) increased use of radiofrequency ablation to the detriment of percutaneous ethanol injection; 5) improved outcomes of ablative and transarterial treatments; 6) improved overall survival (adjusted for the lead time in surveyed patients), particularly after 2009, of both viral and non-viral patients presenting with an early or intermediate stage hepatocellular carcinoma. Conclusions During the last 15 years several etiological and clinical features of hepatocellular carcinoma patients have changed, as their management. The observed improvement of overall survival was due both to the wider use of semiannual surveillance, expanding the proportion of tumors that qualified for curative treatments, and to the improved outcome of locoregional treatments. This article is protected by copyright. All rights reserved.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |